 |
Top 20 Heart disease treatment startups in USA
Sep 29, 2025 | By Jason Kwon | 20 |
1
Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
2
Funding: $1.8B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
3
Funding: $603.2M
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
4
Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
5
Funding: $390.6M
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
6
Funding: $386.5M
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
7
Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
8
Funding: $337.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
9
Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
10
Funding: $300M
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
11
Funding: $290M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
12
Funding: $173.2M
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
13
Funding: $154.3M
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
14
Funding: $145M
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
15
Funding: $141.4M
Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.
Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.
16
Funding: $138.2M
Cutting-edge technology that empowers employees to improve heart health.
Cutting-edge technology that empowers employees to improve heart health.
17
Funding: $129.7M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
18
Funding: $115M
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
19
Funding: $107.1M
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
20
Funding: $102M
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
